Citations

Showing 10 of 108094 citations.

A component method to delineate surgical spine implants for proton Monte Carlo dose calculation
Chang, Chih‐Wei , Charyyev, Serdar , Harms, Joseph , Slopsema, R , Refai, Daniel, Yoon, Tim , Bradley, Jeffrey D. , Yang, Xiaofeng , Lin, Liyong , Bradley, Jeffrey , Lin, Liyong , Wolf, Jonathan, McDonald, Mark William , Leng, Shuai , Zhou, Jun , Yang, Xiaofeng

Mayo Clinic

Journal of Applied Clinical Medical Physics | October 10, 2022 | Volume: 24 | Issue: 1 | Pages: No page available

10.1002/acm2.13800 | PMID 36210177 Get It

AbstractPurposeMetallic implants have been correlated to local control failure for spinal sarcoma and chordoma patients due to the uncertainty of implant delineation from computed tomography (CT). Such uncertainty can compromise the proton Monte Carlo dose calculation (MCDC) accuracy. A component method is proposed to determine the dimension and volume of the implants from CT images.MethodsThe proposed component method leverages the knowledge of surgical implants from medical supply vendors to predefine accurate contours for each implant component, including tulips, screw bodies, lockers, and rods. A retrospective patient study was conducted to demonstrate the feasibility of the method. The reference implant materials and samples were collected from patient medical records and vendors, Medtronic and NuVasive. Additional CT images with extensive features, such as extended Hounsfield units and various reconstruction diameters, were used to quantify the uncertainty of implant contours.ResultsFor in vivo patient implant estimation, the reference and the component method differences were 0.35, 0.17, and 0.04 cm3for tulips, screw bodies, and rods, respectively. The discrepancies by a conventional threshold method were 5.46, 0.76, and 0.05 cm3, respectively. The mischaracterization of implant materials and dimensions can underdose the clinical target volume coverage by 20 cm3for a patient with eight lumbar implants. The tulip dominates the dosimetry uncertainty as it can be made from titanium or cobalt–chromium alloys by different vendors.ConclusionsA component method was developed and demonstrated using phantom and patient studies with implants. The proposed method provides more accurate implant characterization for proton MCDC and can potentially enhance the treatment quality for proton therapy. The current proof‐of‐concept study is limited to the implant characterization for lumbar spine. Future investigations could be extended to cervical spine and dental implants for head‐and‐neck patients where tight margins are required to spare organs at risk.
The Association of Polymorphisms in Genes Encoding Antioxidant Enzymes GPX1 (rs1050450), SOD2 (rs4880) and Transcriptional Factor Nrf2 (rs6721961) with the Risk and Development of Prostate Cancer
Djokic, Milica , Radić, Tanja , Šantrić, Veljko , Dragičević, Dejan , Mihailović, Smiljana , Stanković, Vesna , Cekerevac, Milica, Simić, Tatjana , Nikitović, Marina , Ćorić, Vesna , Simic, Tatjana , Coric, Vesna , Šuvakov, Sonja , Čekerevac, Milica

Mayo Clinic

Medicina | October 9, 2022 | Volume: 58 | Issue: 10 | Pages: 1414

10.3390/medicina58101414 | PMID 36295574 Get It

Background and Objectives: Mounting evidence implicates oxidative damage in prostate carcinogenesis, contributing to modifications of macromolecules that drive cellular malignant transformation. Functional single-nucleotide polymorphisms (SNPs) of enzymes involved in redox homeostasis can disrupt pro-oxidant–antioxidant balance, leading to accumulation of reactive oxygen species and oxidative damage. We investigated the potential role of genetic polymorphisms of antioxidant enzymes glutathione peroxidase 1 (GPX1 rs1050450) and superoxide dismutase 2 (SOD2 rs4880) and regulatory antioxidant protein nuclear factor erythroid 2-related factor 2 (Nrf2 rs6721961) in the susceptibility to prostate cancer development (PC) and prognosis. Materials and Methods: We conducted a case–control study consisting of 235 patients with PC and 240 controls. Gene polymorphisms were determined by quantitative polymerase chain reaction (qPCR) and polymerase chain reaction with confronting two-pair primers (PCR-CTTP) methods. Multiple risk models were composed to inspect the separate and mutual effect of multiple genes and in combination with acquired contributory factors on the risk of PC development. Results: Independently, carriers of at least one SOD2*C allele had increased risk of PC development, which was significantly further amplified in advanced statistical models. When tested in combination, individuals with both SOD2*C allele and Nrf2*C/C genotype were also at increased risk of PC development, which was augmented when combined with acquired contributory factors. During the mean 75 ± 25 months of follow-up, investigated gene polymorphisms did not affect overall survival. Conclusion: Our results suggest that these gene polymorphisms could be used as risk biomarkers of PC evolution.
Cellular Sources and Neuroprotective Roles of Interleukin-10 in the Facial Motor Nucleus after Axotomy
Runge, Elizabeth M. , Setter, Deborah O. , Iyer, Abhirami K. , Regele, Eric J. , Kennedy, Felicia M., Sanders, Virginia M., Jones, Kathryn J.

Mayo Clinic

Cells | October 9, 2022 | Volume: 11 | Issue: 19 | Pages: 3167

10.3390/cells11193167 | PMID 36231129 Get It

Facial motoneuron (FMN) survival is mediated by CD4+ T cells in an interleukin-10 (IL-10)-dependent manner after facial nerve axotomy (FNA), but CD4+ T cells themselves are not the source of this neuroprotective IL-10. The aims of this study were to (1) identify the temporal and cell-specific induction of IL-10 expression in the facial motor nucleus and (2) elucidate the neuroprotective capacity of this expression after axotomy. Immunohistochemistry revealed that FMN constitutively produced IL-10, whereas astrocytes were induced to make IL-10 after FNA. Il10 mRNA co-localized with microglia before and after axotomy, but microglial production of IL-10 protein was not detected. To determine whether any single source of IL-10 was critical for FMN survival, Cre/Lox mouse strains were utilized to selectively knock out IL-10 in neurons, astrocytes, and microglia. In agreement with the localization data reflecting concerted IL-10 production by multiple cell types, no single cellular source of IL-10 alone could provide neuroprotection after FNA. These findings suggest that coordinated neuronal and astrocytic IL-10 production is necessary for FMN survival and has roles in neuronal homeostasis, as well as neuroprotective trophism after axotomy.
Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4
Weiner, Michael W. , Veitch, Dallas P. , Miller, Melanie J. , Aisen, Paul, Albala, Bruce, Harvey, Danielle , Jagust, William J. , Landau, Susan , Morris, John C. , Nosheny, Rachel L. , Okonkwo, Ozioma C. , Perrin, Richard J. , Petersen, Ronald C. , Saykin, Andrew J. , Shaw, Leslie M. , Tosun, Duygu , Trojanowski, John Q. , Initiative, Alzheimer's Disease Neuroimaging, Tosun, Duygu , Saykin, Andrew J , Morris, John C , Harvey, Danielle J , Tosun, Duygu , Beckett, Laurel , Green, Robert C. , Jack, Clifford R. , Mindt, Mónica Rivera , Toga, Arthur W. , Initiative, Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | October 9, 2022 | Volume: 19 | Issue: 1 | Pages: 307-317

10.1002/alz.12797 | PMID 36209495 Get It

AbstractIntroductionThe Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for Alzheimer's disease (AD) clinical trials. To improve generalizability, ADNI4 aims to enroll 50‐60% of its new participants from underrepresented populations (URPs) using new biofluid and digital technologies. ADNI4 has received funding from the National Institute on Aging beginning September 2022.MethodsADNI4 will recruit URPs using community‐engaged approaches. An online portal will screen 20,000 participants, 4000 of whom (50‐60% URPs) will be tested for plasma biomarkers and APOE. From this, 500 new participants will undergo in‐clinic assessment joining 500 ADNI3 rollover participants. Remaining participants (∼3500) will undergo longitudinal plasma and digital cognitive testing. ADNI4 will add MRI sequences and new PET tracers. Project 1 will optimize biomarkers in AD clinical trials.Results and DiscussionADNI4 will improve generalizability of results, use remote digital and blood screening, and continue providing longitudinal clinical, biomarker, and autopsy data to investigators.
Cardiovascular Complications of Obstructive Sleep Apnea in the Intensive Care Unit and Beyond
Jain, Nitesh , Surani, Salim , Mushtaq, Hisham, Mir, Mikael, Jama, Abbas B, Rauf, Ibtisam , Jain, Shikha , Korsapati, Aishwarya Reddy, Chandramouli, Mantravadi Srinivasa, Boike, Sydney , Attallah, Noura , Hassan, Esraa, Chand, Mool, Bawaadam, Hasnain , Khan, Syed Anjum , Jain, Nitesh Kumar , Surani, Salim , Jama, Abbas Bashir, Boike, Sydney , Khan, Syed Anjum , Wahab, Abdul , Chowdhury, Arnab Roy , Khedr, Anwar

Mayo Clinic

Medicina | October 9, 2022 | Volume: 58 | Issue: 10 | Pages: 1390

10.3390/medicina58101390 | PMID 36295551 Get It

Obstructive sleep apnea (OSA) is a common disease with a high degree of association with and possible etiological factor for several cardiovascular diseases. Patients who are admitted to the Intensive Care Unit (ICU) are incredibly sick, have multiple co-morbidities, and are at substantial risk for mortality. A study of cardiovascular manifestations and disease processes in patients with OSA admitted to the ICU is very intriguing, and its impact is likely significant. Although much is known about these cardiovascular complications associated with OSA, there is still a paucity of high-quality evidence trying to establish causality between the two. Studies exploring the potential impact of therapeutic interventions, such as positive airway pressure therapy (PAP), on cardiovascular complications in ICU patients are also needed and should be encouraged. This study reviewed the literature currently available on this topic and potential future research directions of this clinically significant relationship between OSA and cardiovascular disease processes in the ICU and beyond.
PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations
Crowson, Cynthia S. , Warrington, Kenneth J. , Zand, Ladan , Sethi, Sanjeev , Fervenza, Fernando C. , Crowson, CS , Warrington, Kenneth J , Sethi, Sanjeev , Fervenza, Fernando C , Moura, Marta Casal , Specks, Ulrich

Mayo Clinic

Clinical Kidney Journal | October 9, 2022 | Volume: 16 | Issue: 3 | Pages: 432-436

10.1093/ckj/sfac221 | PMID 36865008 Get It

ABSTRACTThe risk of progression to end-stage kidney disease (ESKD) in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and glomerulonephritis (AAV-GN) remains high. At 5 years of follow-up, 14–25% of patients will evolve to ESKD, suggesting that kidney survival is not optimized in patients with AAV. The addition of plasma exchange (PLEX) to standard remission induction has been the standard of care, particularly in patients with severe renal disease. However, there is still some debate regarding which patients benefit from PLEX.A recently published meta-analysis concluded that the addition of PLEX to standard remission induction in AAV probably reduced the risk of ESKD at 12 months and that PLEX was associated with an estimated absolute risk reduction for ESKD at 12 months of 16.0% for those at high risk or with a serum creatinine >5.7 mg/dl (high certainty of important effects). These findings were interpreted as supportive of offering PLEX to patients with AAV and a high risk of progression to ESKD or requiring dialysis and are making their way into societies recommendations.However, the results of the analysis can be debated. We provide an overview on the meta-analysis as an attempt to guide the audience through how the data were generated, to comment on our interpretation of the results and to explain why we feel uncertainty remains. In addition, we would like to provide insights in two questions that we believe are very relevant to consider when addressing the role of PLEX: the role of kidney biopsy findings in the decision making of whom might benefit from PLEX and the impact of novel treatments (i.e. complement factor 5a inhibitors) in avoiding progression to ESKD at 12 months. The treatment of patients with severe AAV-GN is complex and further studies that include only patients at high risk of progression to ESKD are needed.
Pneumatosis Intestinalis Induced by Alpha-Glucosidase Inhibitors in Patients with Diabetes Mellitus
McKinley, Blake , Santiago, Mariângela, Pak, Christi , Nguyen, Nataly, Zhong, Qing Peter Wild , McKinley, Blake J , Zhong, Qing , Santiago, Mariangela

Mayo Clinic

Journal of Clinical Medicine | October 8, 2022 | Volume: 11 | Issue: 19 | Pages: 5918

10.3390/jcm11195918 | PMID 36233785 Get It

Alpha-glucosidase inhibitor (αGIs)-induced pneumatosis intestinalis (PI) has been narrated in case reports but never systematically investigated. This study aimed to investigate the concurrency of PI and αGIs. A literature search was performed in PubMed, Google Scholar, WorldCat, and the Directory of Open-Access Journals (DOAJ) by using the keywords “pneumatosis intestinalis”, “alpha-glucosidase inhibitors”, and “diabetes”. In total, 29 cases of αGIs-induced PI in 28 articles were included. There were 11 men, 17 women, and one undefined sex, with a median age of 67. The most used αGI was voglibose (44.8%), followed by acarbose (41.4%) and miglitol (6.8%). Nine (31%) patients reported concomitant use of prednisone/prednisolone with or without immunosuppressants. The main symptoms were abdominal pain (54.5%) and distention (50%). The ascending colon (55.2%) and the ileum (34.5%) were the most affected. Nineteen (65.5%) patients had comorbidities. Patients with comorbidities had higher rates of air in body cavities, the portal vein, extraintestinal tissues, and the wall of the small intestine. Only one patient was found to have non-occlusive mesenteric ischemia. Twenty-five patients were treated with conservative therapy alone, and two patients received surgical intervention. All patients recovered. In conclusion, comorbidities, glucocorticoids, and immunosuppressants aggravate αGIs-induced PI. Conservative therapy is recommended when treating αGIs-induced PI.
Harnessing the Molecular Fingerprints of B Cell Lymphoma for Precision Therapy
Mensah, Afua A. , Mensah, Afua Adjeiwaa , Mondello, Patrizia

Mayo Clinic

Journal of Clinical Medicine | October 8, 2022 | Volume: 11 | Issue: 19 | Pages: 5834

10.3390/jcm11195834 | PMID 36233702 Get It

The last two decades have brought ground-breaking advances in genetics, culminating in deep profiling of the human genome and high resolution detection of genetic variants [...]
Effect of Face Masks on Physiological and Perceptual Responses during 30 Minutes of Self-Paced Exercise in Older Community Dwelling Adults
Vogt, Grace, Radtke, Kimberley, Jagim, Andrew R. , Peckumn, Dominique, Lee, Teresa , Mikat, Richard P., Foster, Carl , Jagim, Andrew R

Mayo Clinic

International Journal of Environmental Research and Public Health | October 8, 2022 | Volume: 19 | Issue: 19 | Pages: 12877

10.3390/ijerph191912877 | PMID 36232176 Get It

This study examined the effects of different types of masks (no mask, surgical mask (SM), and N95-mask) on physiological and perceptual responses during 30-min of self-paced cycle ergometer exercise. This study was a prospective randomly assigned experimental design. Outcomes included workload (Watts), oxygen saturation (SpO2), end-tidal carbon dioxide (PetCO2), heart rate (HR), respiratory rate (RR), rating of perceived exertion (RPE), and rating of perceived dyspnea (RPD). Volunteers (54–83 years (n = 19)) completed two familiarization sessions and three testing sessions on an air braked cycle ergometer. No significant difference was found for condition x time for any of the dependent variables. RPE, RPD, and PetCO2 were significantly higher with an N95-mask vs. no mask (NM) ((p = 0.012), (p = 0.002), (p < 0.001)). HR was significantly higher with the SM compared to the NM condition (p = 0.027) (NM 107.18 ± 9.96) (SM 112.34 ± 10.28), but no significant difference was found when comparing the SM to the N95 condition or when comparing the N95condition to the NM condition. Watts increased across time in each condition (p = 0.003). Initially RR increased during the first 3 min of exercise (p < 0.001) with an overall gradual increase noted across time regardless of mask condition (p < 0.001). SpO2 significantly decreased across time but remained within normal limits (>95%). No significant difference was found in Watts, RR, or SpO2 regardless of mask condition. Overall, the N95mask was associated with increased RPE, RPD, and PetCO2 levels. This suggests trapping of CO2 inside the mask leading to increased RPE and RPD.
Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future
Ruch, Brianna , Wagler, Josiah , Kumm, Kayla , Zhang, Chi , Katariya, Nitin , García-Saenz-de-Sicilia, Mauricio , Giorgakis, Emmanouil , Mathur, Amit K. , Katariya, Nitin N , Mathur, Amit , Giorgakis, Emmanouil

Mayo Clinic

Current Oncology | October 8, 2022 | Volume: 29 | Issue: 10 | Pages: 7537-7551

10.3390/curroncol29100593 | PMID 36290870 Get It

Hepatocellular carcinoma (HCC) is one of the leading indications for liver transplantation and has been the treatment of choice due to the oncologic benefit for patients with advanced chronic liver disease (AdvCLD) and small tumors for the last 25 years. For HCC patients undergoing liver transplantation, alpha fetoprotein (AFP) has increasingly been applied as an independent predictor for overall survival, disease free recurrence, and waitlist drop out. In addition to static AFP, newer studies evaluating the AFP dynamic response to downstaging therapy show enhanced prognostication compared to static AFP alone. While AFP has been utilized to select HCC patients for transplant, despite years of allocation policy changes, the US allocation system continues to take a uniform approach to HCC patients, without discriminating between those with favorable or unfavorable tumor biology. We aim to review the history of liver allocation for HCC in the US, the utility of AFP in liver transplantation, the implications of weaving AFP as a biomarker into policy. Based on this review, we encourage the US transplant community to revisit its HCC organ allocation model, to incorporate more precise oncologic principles for patient selection, and to adopt AFP dynamics to better stratify waitlist dropout risk.